Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped royalty purchase agreement with Sobi under which ...

C3.ai(NYSE: AI) is generating accelerating revenue growth and improving free cash flow. It also boasts a pristine balance sheet. Where to invest $1,000 right now? Our analyst team just revealed what ...

C3.ai, Inc. (AI) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some ...

Investing.com -- Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) stock surged 12% after the U.S. Food and Drug Administration (FDA) approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 ...

C3.ai has the ingredients to build a sustainable enterprise AI business. There are risks that could derail C3.ai's expansion.

To get a sense of who is truly in control of C3.ai, Inc. , it is important to understand the ownership structure of the business. We can see that institutions own the lion's share ...

These two companies are both leading the artificial intelligence charge, but one business stands out as superior.

The stocks bucked a mostly optimistic broader market, with the tech-heavy Nasdaq and the S&P 500 both up by 0.18 percent and ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

C3.Ai Inc AI shares are falling Thursday after the company announced a planned CEO transition. What To Know: C3.ai said it ...

Trump’s AI Action Plan drops Wednesday, and AI stocks like NVIDIA are priced for perfection. Here’s why I’m taking a sell-the-news approach with an August 15 $170 NVDA put—and what could go wrong (or ...

Romanian clients of NAGA placed the highest number of trades in Banca Transilvania, BRD and Hidroelectrica, while globally, ...